BTN News: Frontier Science Scotland (FSS), a respected Clinical Research Organization that continues to be highly successful in supporting drug development with excellent clinical trials, is proud to introduce Bjoern Schelter as a new Director of the Board of Trustees. This key strategic hire will expand Bjoern’s extensive experience in data management, biostatistical analysis, and quality assurance thereby amplifying The FSS dedication to quality.
Leadership and Expertise
Prof Bjoern Schelter, who is currently CEO of GT Diagnostics (UK) Ltd and Chief Analytics Officer of TauRx Therapeutics, and is also a Professor of Applied Mathematics at the University of Aberdeen. With over 20 years in the Healthcare industry, Bjoern has been leading research teams since 2006. In his work, his research focus is on building data science capabilities to improve our understanding of diseases and patient outcomes worldwide.
Support of FSS Leadership
FSS Board of Trustees Chair Professor Chris Robertson, who is also a leading academic in the Department of Mathematics and Statistics at the University of Strathclyde, welcomed the new appointment. We are absolutely thrilled to have Bjoern join the FSS Board of Trustees. This wealth of experience in quality assurance in clinical trials data-science-based healthcare R&D and strong leadership will prove invaluable as we extend our service offerings across global industry partners.
Professor Schelter’s Vision
Reflecting on his appointment, Professor Bjoern Schelter expressed his vision for FSS: “I am very excited about FSS and its exceptional services within a non-profit-based concept. This is why I am proud to be a part of the FSS Board. I am really excited to be able to help FSS reflect their service and organizational growth.
Frontier Science Scotland
About FSS FSS is a premier global clinical data research organization (CRO) that advances the clinical and regulatory development of new drugs, through its high quality clinical development services. It provides a wide range of biostatistical, data management and quality assurance services to a broad spectrum of commercial and academic customers worldwide. Services cover the complete spectrum of activities related to the design, feasibility execution, management and analysis of clinical trials.
A trusted provider in the clinical research industry, FSS offers expertise in the support of large global Phase II and III clinical trials in oncology, neurology (including mental health) and respiratory disease, and other therapeutic areas with extensive clinical experience. Formed in the Scottish Highlands by a group of engineers, over two decades ago, the organisation has progressed to become an experienced team. Several team members have advanced degrees and hold positions nationally and internationally on trial steering committees, funding review panels and human research ethics committees.
Collaborative Excellence
Central to FSS’s success is that collaborative effort as ensuring partnerships are seamless is pivotal to the success of the clinical trials. Biostatisticians have this critical expertise in choosing the suitable statistics analysis methods to test against the hypothesis, leading to the proper results which is also interpretable. No matter how small, experimental, or complex the trial is, the data management services keep the datasets scrupulous, precise, and dependable for analysis. FSS also offers regulatory compliance consulting, quality management systems, and technical writing services, giving all involved the peace of mind about presentations of trial outcomes.
Expanded Services
FSS also provides a range of additional services including regulatory writing, medical communications and medical device consultancy, with strategic technology licensing, through partnerships with Alchemy and iDE8. These partnerships with international oncology organisations including Belgium’s Breast International Group (BIG) and the Jules Bordet Institute (IJB) and the Frontier Science Foundation (FSF) enhance FSS’ innovative data management and analytics in clinical trials.
FSS continues to be staunchly independent and not-for-profit in support of seeking and finding the way forward in clinical research to move health forward.
